CABA Cabaletta Bio, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1759138 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-19.5%
TTM EPS YoY44.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-89.5%
ROA-72.0%
ROIC (approx.)-479.6%
Asset turnover—
Leverage & solvency
Liabilities / assets15.6%
Debt / equity0.00x
Current ratio6.55x
Interest coverage-87.26x
Cash quality & payout
Operating cash flow / net income0.86x
Accruals ratio-10.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $142.67M | $97.20M |
| SG&A expense | $29.57M | $27.94M |
| Operating income | -$172.24M | -$125.14M |
| Interest expense | $2.00M | $748,000 |
| Income tax | $0 | $0 |
| Net income | -$167.86M | -$115.86M |
| EBITDA | -$170.59M | -$123.43M |
| EPS (basic) | -2.10 | -2.34 |
| EPS (diluted) | -2.10 | -2.34 |
| Balance sheet | ||
| Cash & equivalents | $82.98M | $163.96M |
| Short-term investments | $50.62M | $0 |
| Current assets | $138.87M | $166.68M |
| PP&E, net | $1.92M | $2.74M |
| Total assets | $165.08M | $185.05M |
| Current liabilities | $50.15M | $27.09M |
| Total liabilities | $53.03M | $32.71M |
| Shareholders' equity | $112.05M | $152.34M |
| Shares outstanding | 100.48M | 50.74M |
| Cash flow statement | ||
| Operating cash flow | -$131.08M | -$88.22M |
| Capital expenditure | $1.23M | $2.21M |
| Free cash flow | -$132.31M | -$90.43M |
| Investing cash flow | -$50.27M | $47.29M |
| Financing cash flow | $100.35M | $11.68M |
| Depreciation & amortization | $1.65M | $1.71M |
| Stock-based compensation | $20.94M | $19.46M |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.